RNS Number : 1214C
Genedrive PLC
05 February 2020

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 125,000 ordinary shares of 1.5p each ("Ordinary Shares") today at 8p per share and Tom Lindsay, Non-Executive Director, acquired 125,000 Ordinary Shares today at 8p per share.

Gino Miele, R&D Director and a PDMR, acquired 27,798 Ordinary Shares in the Company at a price of 11.56p per share yesterday and acquired 20,921 Ordinary Shares at 9.5p per share today.

Following these purchases, Dr Ian Gilham is interested in 490.674 Ordinary Shares, 1.4% of the issued share capital of the Company, Tom Lindsay is interested in 190,217 Ordinary Shares, 0.5% of the issued share capital of the Company and Gino Miele is interested in 56,719 Ordinary Shares, 0.2% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	***Details of the person discharging managerial responsibilities / person closely associated***	
a.	*Name*	*1. Ian Gilham* *2. Tom Lindsay*
2.	***Reason for the notification***	
a.	*Position/status*	*1. Non-Executive Chairman* *2. Non-Executive Director*
a.	*Initial notification /Amendment*	*Initial notification*
3.	***Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor***	
a.	*Name*	*genedrive plc*
b.	*LEI*	*213800ZYODIRZ87Y4K14*
4.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	
a.	*Description of the Financial instrument, type of instrument Identification code*	*Ordinary shares of 1.5 pence each* *GB00B1VKB244*
b.	*Nature of the*	*Purchase*

	transaction	
c.	*Price(s) and volume(s)*	<table><tr><th>*Price(s)*</th><th>*Volume(s)*</th></tr><tr><td>*1. 8p*</td><td>*1. 125,000*</td></tr><tr><td>*2. 8p*</td><td>*3. 125,000*</td></tr></table>
d.	*Aggregated information* · *Aggregated volume* · *Price*	*N/A*
e.	*Date of the transaction*	*2020-02-05*
f.	*Place of the transaction*	*London Stock Exchange, AIM*

1.	***Details of the person discharging managerial responsibilities / person closely associated***	
b.	*Name*	*Gino Miele*
2.	***Reason for the notification***	
c.	*Position/status*	*R&D Director*
b.	*Initial notification /Amendment*	*Initial notification*
3.	***Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor***	
g.	*Name*	*genedrive plc*
h.	*LEI*	*213800ZYODIRZ87Y4K14*
4.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	
i.	*Description of the Financial instrument, type of instrument* *Identification code*	*Ordinary shares of 1.5 pence each* *GB00B1VKB244*
j.	*Nature of the transaction*	*Purchase*
k.	*Price(s) and volume(s)*	<table><tr><th>*Price(s)*</th><th>*Volume(s)*</th></tr><tr><td>*11.56p*</td><td>*27,798*</td></tr></table>
l.	*Aggregated information* · *Aggregated volume* · *Price*	*N/A*
m.	*Date of the transaction*	*2020-02-04*
n.	*Place of the transaction*	*London Stock Exchange, AIM*

5.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	
a.	*Description of the Financial instrument, type of instrument Identification code*	*Ordinary shares of 1.5 pence each* *GB00B1VKB244*
b.	*Nature of the transaction*	*Purchase*
c.	*Price(s) and volume(s)*	*Price(s)* / *Volume(s)*: *9.5p* / *20,921*
d.	*Aggregated information* · *Aggregated volume* · *Price*	*N/A*
e.	*Date of the transaction*	*2020-02-05*
f.	*Place of the transaction*	*London Stock Exchange, AIM*

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker) +44 (0)20 3815 8880
Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAXASEDEEEFA